Carboplatin/etoposide in small cell lung cancer.
Carboplatin/etoposide is an active combination in small cell lung cancer. In phase II studies, it produces results that appear equivalent to cisplatin/etoposide, but it has not been compared in a randomized study. It has a better toxicity profile than cisplatin/etoposide when compared in non-small cell lung cancer. The combination of carboplatin/etoposide is very well tolerated by elderly patients. Carboplatin/etoposide lacks important nonhematologic side effects, which has led to its assessment in dose escalation studies with colony-stimulating factors and autologous bone marrow transplantation.
Bishop
J F
JF
Department of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*
D016298:Hematopoietic Cell Growth Factors; D005047:Etoposide; D016190:Carboplatin